Q-omics provides the consensus-scored NPEPL1 profile across patient tissues and cancer cell-line models. NPEPL1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NPEPL1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, NPEPL1 protein abundance shows 24,102 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, and LUAD as cancer lineages where NPEPL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPEPL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPEPL1 survival associations across molecular data types. NPEPL1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPEPL1 RNA expression–survival associations across cancer types. High NPEPL1 expression shows unfavorable associations in KIRC, UVM, LGG and LIHC, but favorable associations in SCLC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NPEPL1 RNA expression.
This table summarizes NPEPL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NPEPL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPEPL1 shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, LIHC, CHOL and HNSC. The KIRC box plot shows higher NPEPL1 RNA expression in tumor versus normal tissue (log2 FC = +0.780, t-test p < 0.001).
This table shows molecular features associated with NPEPL1 in patient tissues and cancer cell lines. In patient samples, NPEPL1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NPEPL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
